{"id":"nrt6003-injection","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a radiomedicine product from Chengdu New Radiomedicine Technology Co. LTD., NRT6003 likely functions as a theranostic or therapeutic radiopharmaceutical that combines a radionuclide with a targeting vector to deliver localized radiation to tumor tissue while minimizing systemic exposure. The specific mechanism depends on the radionuclide used and the targeting moiety, which are not publicly disclosed in available sources.","oneSentence":"NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:26.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06310590","phase":"PHASE1","title":"Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2023-08-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06900543","phase":"PHASE3","title":"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2025-04-15","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT06909708","phase":"NA","title":"SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-04-03","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yttrium-90 carbon microspheres"],"phase":"phase_3","status":"active","brandName":"NRT6003 Injection","genericName":"NRT6003 Injection","companyName":"Chengdu New Radiomedicine Technology Co. LTD.","companyId":"chengdu-new-radiomedicine-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NRT6003 is a radiopharmaceutical injection designed to deliver targeted radiation therapy to cancer cells. Used for Cancer (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}